TABLE 1.
Clinicopathological features
| Overall n = 573 | < 3 SLNs retrieved n = 42 | > 3 SLNs retrieved n = 531 | P* | ALND avoided n = 237 | ALND required n = 336 | P* | |
|---|---|---|---|---|---|---|---|
| Age, years | 49 (24, 82) | 53 (36, 78) | 49 (24, 82) | 0.07 | 49 (24, 82) | 50 (27, 78) | 0.08 |
| BMI, kg/m2 | 25.8 (15.9, 68.3) | 28.4 (17.4, 47.5) | 25.7 (15.9, 68.2) | 0.01 | 25.6 (16.9, 68.2) | 26.1 (15.9, 47.5) | 0.24 |
| Palpable node at presentation | 0.84 | 0.55 | |||||
| No | 146 | 10 (7%) | 136 (93%) | 55 (38%) | 91 (62%) | ||
| Borderline | 13 | 0 (0%) | 13 (100%) | 6 (46%) | 7 (54%) | ||
| Yes | 414 | 32 (8%) | 382 (92%) | 176 (43%) | 238 (57%) | ||
| Palpable tumor at presentation | 0.19 | 0.23 | |||||
| No | 59 | 6 (10%) | 53 (90%) | 26 (44%) | 33 (56%) | ||
| Borderline | 12 | 2 (17%) | 10 (83%) | 2 (17%) | 10 (83%) | ||
| Yes | 502 | 34 (7%) | 468 (93%) | 209 (42%) | 293 (58%) | ||
| Clinical T at presentation | 0.03 | 0.85 | |||||
| 1 | 110 | 6 (5%) | 104 (95%) | 42 (38%) | 68 (62%) | ||
| 2 | 334 | 19 (6%) | 315 (94%) | 141 (42%) | 193 (57%) | ||
| 3 | 125 | 16 (13%) | 109 (87%) | 52 (41%) | 73 (58%) | ||
| X | 4 | 1 (25%) | 3 (75%) | 2 (50%) | 2 (50%) | ||
| Subtype | 0.55 | < 0.001 | |||||
| HR+ HER2− | 241 | 14 (6%) | 227 (94%) | 49 (20%) | 192 (80%) | ||
| HR+ HER2+ | 138 | 13 (9%) | 125 (91%) | 76 (55%) | 62 (45%) | ||
| HR− HER2+ | 80 | 7 (9%) | 73 (91%) | 62 (78%) | 18 (23%) | ||
| HR− HER2− | 114 | 8 (7%) | 106 (93%) | 50 (44%) | 64 (56%) | ||
| Histology | 0.60 | 0.002 | |||||
| Ductal | 437 | 31 (7%) | 406 (93%) | 194 (44%) | 243 (56%) | ||
| Lobular and mixed | 41 | 2 (5%) | 39 (95%) | 7 (17%) | 34 (83%) | ||
| Micropapillary and mixed | 36 | 5 (14%) | 31 (86%) | 10 (28%) | 26 (72%) | ||
| Apocrine and mixed | 40 | 3 (8%) | 37 (93%) | 20 (50%) | 20 (50%) | ||
| Other | 19 | 1 (5%) | 18 (95%) | 6 (32%) | 13 (68%) | ||
| LVI† | 213 | 23 (11%) | 190 (89%) | 0.02 | 46 (22%) | 167 (78%) | < 0.001 |
| Grade | 0.72 | < 0.001 | |||||
| I | 7 | 0 (0%) | 7 (100%) | 1 (14%) | 6 (86%) | ||
| II | 228 | 19 (8%) | 209 (92%) | 55 (24%) | 173 (76%) | ||
| III | 338 | 23 (7%) | 315 (93%) | 181 (54%) | 157 (46%) |
Frequency (row percent) reported for categorical variables and median (range) reported for continuous variables
*
Results from Fisher’s exact test for categorical variables and Wilcoxon rank-sum test for continuous variables
†
LVI was present on core biopsy or final biopsy
SLN sentinel lymph node, pCR pathologic complete response, BMI body mass index, HR hormone receptor, LVI lymphovascular invasion